Table 5. Neutralization activity of BCN samples against DU156 pseudovirus with mutations in peptidoglycans targeted by the PG9/PG16 and PGT series of bNAbs.
| Sample ID | ID50 | Fold change* | |||
|---|---|---|---|---|---|
| DU156WT | N160K | N332A | N160K | N332A | |
| NAB016 | 811.6 | 645.7 | 513.7 | 1.3 | 1.6 |
| NAB033 | 623.8 | 580 | 310.9 | 1.1 | 2.0 |
| NAB046 | 1827 | 7852 | 556.6 | 0.2 | 3.3 |
| NAB059 | 1316 | 5500 | 970.7 | 0.2 | 1.4 |
| NAB062 | 6400 | 255.8 | 263.6 | 25.0 | 24.3 |
| NAB063 | 726.5 | 775 | 883.3 | 0.9 | 0.8 |
| NAB065 | 468.2 | 609.4 | 184.4 | 0.8 | 2.5 |
| NAB069 | 3328 | 1675 | 940 | 2.0 | 3.5 |
| HHP | <10 | <10 | <10 | NA | NA |
*Fold change = ID50 of HIV-1DU156WT/ID50 of HIV-1DU156 mutant. Values with fold changes ≥3.0 are highlighted in bold format.
NA, Not Applicable.